STL Index for: Crisaborole

The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.

This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.

Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

Index of STL articles for Volume 24 (2019). Articles are indexed by drug names, trade names and disease terms. Use the main navigation (A, B, C..) to navigate through this index and use the reference links (i.e. 4:5-9) to see the sources.

Atopic dermatitis (AD) is a chronic and pruritic inflammatory disease that affects a wide age range of patients causing significant impact on their quality of life. There has been a recently updated consensus paper on the treatment of mild-to-moderate AD published by an expert panel of dermatologists and pediatricians. Family physicians are well equipped to manage...

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.

A list of skin treatments introduced in 2018, categorized by type/class of therapy. The content primarily focuses on approvals issued by US and Canadian drug regulatory agencies and is sourced from both regulatory and industry news releases.

An overview to AD care and focus our review to topical agents used in AD including topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) and discuss the newest topical agent accessible in the physician's armamentarium, crisaborole.

Updates on Binimetinib + Encorafenib (Mektovi® + Braftovi®), Crisaborole 2% ointment (Eucrisa™), Glycopyrronium tosylate 2.4% cloth (Qbrexza™), Secukinumab for SC injection (Consentyx®), Tecovirimat capsule (Tpoxx), Diacerein 1% ointment (CCP-020), Migalastat capsule (Galafold™), Mogamulizumabkpkc for IV use (Poteligeo®)

The list covers new skin treatments for Actinic Keratosis, Hemangioma, Hidradenitis Suppurativa, as well as Anti-acne Agents, Antibacterial Agents, Anti-cancer Agents, Dermal Fillers, Neuromodulator and other treatments and drugs.

Update on drugs, approval dates, and comments for Nivolumab + ipilimumab (Opdivo® + Yervoy®), Etanercept for SC injection (Enbre®), Crisaborole 2% ointment (Eucrisa™ ), Hyaluronic acid dermal fillers Restylane® (Refyne Restylane® Defyne).